BioMarin assumed with a Buy at UBS
UBS analyst Joon Lee assumed coverage of BioMarin (BMRN) with a Buy rating and $88 price target The firm views the company as a turnaround story. Management changes that took…
Fiscal Year: January - December
BioMarin Pharmaceutical Inc. (BMRN), listed on the NASDAQ, has a market capitalization of $10.58B. As of Oct 18, 2026, the stock is trading at $54.68 per share@else an unavailable price , offering investors a clear view of its current market value. BioMarin Pharmaceutical Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 144.28, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. BioMarin Pharmaceutical Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that BioMarin Pharmaceutical Inc. (BMRN) has a DCF fair value that is only shown to premium members. To see it, please Login or Upgrade for access.
The proprietary SS Score for BioMarin Pharmaceutical Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for BioMarin Pharmaceutical Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for BioMarin Pharmaceutical Inc. is 14.34, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, BioMarin Pharmaceutical Inc. (BMRN) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether BioMarin Pharmaceutical Inc. (BMRN) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of BioMarin Pharmaceutical Inc. (BMRN) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of BioMarin Pharmaceutical Inc.. To access the full SS Score, consider upgrading your subscription.
BioMarin Pharmaceutical Inc. is a significant player in the industry sector, with a market capitalization of $10.58B and a competitive P/E ratio of 144.28. Investors should compare these metrics with industry peers to gauge whether BioMarin Pharmaceutical Inc. is outperforming or underperforming within its sector.
UBS analyst Joon Lee assumed coverage of BioMarin (BMRN) with a Buy rating and $88 price target The firm views the company as a turnaround story. Management changes that took…
Barclays raised the firm’s price target on BioMarin (BMRN) to $114 from $111 and keeps an Overweight rating on the shares as part of a Q3 earnings preview. BioMarin “sounds…
BioMarin (BMRN) Pharmaceutical announced it will present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting in Boston, including results from studies…
New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants SAN RAFAEL, Calif., Oct. 9, 2026 /PRNewsw...
BioMarin (BMRN) Pharmaceutical announced that Cara Bauer, Ph.D., has been named Executive Vice President, Chief People Officer. Bauer will assume responsibility for the company’s Human Resources organ...
Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ --...
A BioMarin combination therapy helped adults with late-onset Pompe disease maintain walking distance over five years of continuous therapy. Respiratory function remained relatively stable, with no new...
BioMarin (BMRN) Pharmaceutical announced new data evaluating the efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease were presented at the 31st Annual Congress of the World Muscle…
Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease SAN RAFAEL, Calif., Oct. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) tod...
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $BMRN--Profluent, the frontier AI lab for biology, today announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapi...
BMO Capital lowered the firm’s price target on BioMarin (BMRN) to $97 from $98 and keeps an Outperform rating on the shares after the company discontinued development of Voxzogo in…
In a regulatory filing, BioMarin (BMRN) Pharmaceutical disclosed its decision to discontinue development of Voxzogo for children with Noonan syndrome. “BioMarin made this decision after assessing a nu...
BioMarin Pharmaceutical (BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company’s Board of Directors, effective September 10. Dr. Plenge is Executive Vice President,...
SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D.
BioMarin (BMRN) Pharmaceutical announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO, or vosoritide, in children with hypochondroplasia were published in New England Journal of Med...
Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual ...
Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST Cantor Global Healthcare Conference 2026, September 10 at 10:20 am EST Citi's 2026 Biopharma Back to School Conference, Septem...
BioMarin Pharmaceutical (BMRN) said that it completed the previously announced agreement to acquire Alesta Therapeutics. The acquisition will strengthen BioMarin’s skeletal conditions portfolio, addin...
Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline SAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today...
Cantor Fitzgerald raised the firm’s price target on BioMarin (BMRN) to $86 from $85 and keeps an Overweight rating on the shares after the company reached a settlement with Ascendis…
Piper Sandler analyst Allison M. Bratzel raised the firm’s price target on BioMarin (BMRN) to $90 from $88 and keeps an Overweight rating on the shares on news of a…
Projected from reported cash flow (SEC filings). The starting point is the latest yearly revenue times the median free cash flow margin of the last five years. Years 1 to 5 grow at the revenue growth rate of the last five years (between -5% and 15%), and years 6 to 10 slow down to the 2.5% perpetual growth rate. These are Studying Stocks' own estimates, not analyst forecasts, and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | Source |
|---|---|---|---|
| 2026 | 406.88M | 11.60% | Projected |
| 2027 | 454.10M | 11.60% | Projected |
| 2028 | 506.79M | 11.60% | Projected |
| 2029 | 565.60M | 11.60% | Projected |
| 2030 | 631.24M | 11.60% | Projected |
| 2031 | 693.00M | 9.78% | Projected |
| 2032 | 748.18M | 7.96% | Projected |
| 2033 | 794.13M | 6.14% | Projected |
| 2034 | 828.44M | 4.32% | Projected |
| 2035 | 849.15M | 2.50% | Projected |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 487.42M | 1.00 | 487.42M |
| 2025A | 724.96M | 1.00 | 724.96M |
| 2026E | 406.88M | 1.07 | Login |
| 2027E | 454.10M | 1.15 | Login |
| 2028E | 506.79M | 1.24 | Login |
| 2029E | 565.60M | 1.33 | Login |
| 2030E | 631.24M | 1.43 | Login |
| 2031E | 693.00M | 1.53 | Login |
| 2032E | 748.18M | 1.64 | Login |
| 2033E | 794.13M | 1.76 | Login |
| 2034E | 828.44M | 1.89 | Login |
| 2035E | 849.15M | 2.03 | Login |
| Terminal | 2.03 | Login |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.